Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FR239087
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
FR239087 is an experimental small molecule inhibitor of adenosine deaminase. It belongs to the class of organic compounds known as dichlorobenzenes and has the chemical formula C15H17Cl2N3O2. The compound was rationally designed as a non-nucleoside, potent, and orally bioavailable adenosine deaminase inhibitor, with the aim of modulating purine metabolism by inhibiting this enzyme[1][4]. Its primary mechanism is competitive inhibition of adenosine deaminase, which may have implications for immunomodulation or anticancer activity; however, it has not advanced beyond preclinical or very early clinical development[1][3][4].
- Other names
- PD007044PD-007044PD 007044
02
Targets
ADA (Adenosine deaminase)
Beyond the preview
Go deeper on FR239087.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FR239087.